SCHEMBL3663708

SCHEMBL3663708

CCOC(=O)N1CCn2c(nc(-c3ccncc3)cc2=O)C(NC)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 7/20 0.44
GSK3B P49841 5/20 0.43
CDC7 O00311 1/20 0.43
ROCK2 O75116 1/20 0.43
PIM1 P11309 1/20 0.43
HIPK2 Q9H2X6 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
HRH2 P25021 1/20 0.40
HRH1 P35367 1/20 0.40
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL915676 0.86 GSK3B (0.44) P2RY12GSK3BCDC7ROCK2PIM1
SCHEMBL15158304 0.84 MEN1 (0.41) P2RY12GSK3BCDC7ROCK2PIM1
SCHEMBL3657923 0.83 NOS1 (0.44) P2RY12GSK3BHRH2HRH1MAPT
SCHEMBL3667749 0.82 HPGD (0.40) P2RY12GSK3BCDC7ROCK2PIM1
SCHEMBL3659187 0.81 P2RY12 (0.41) P2RY12GSK3BCDC7ROCK2PIM1
SCHEMBL3660413 0.81 KCNMA1 (0.41) P2RY12GSK3BCDC7ROCK2PIM1
SCHEMBL3664429 0.81 GSK3B (0.43) P2RY12GSK3BCDC7ROCK2PIM1
SCHEMBL3664954 0.80 GSK3B (0.37) P2RY12GSK3BCDC7ROCK2PIM1
SCHEMBL3658002 0.80 P2RY12 (0.38) P2RY12GSK3BCDC7ROCK2PIM1
SCHEMBL3663855 0.78 USP30 (0.42) P2RY12ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2238141-A1 SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA Sanofi-Aventis (FR) 2010-10-13 EP disclosed
WO-2009095789-A1 SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA SANOFI-AVENTIS (FR) 2009-08-06 WO disclosed